Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,221,477
  • Shares Outstanding, K 21,100
  • Annual Sales, $ 141,100 K
  • Annual Income, $ 12,560 K
  • 36-Month Beta 1.06
  • Price/Sales 30.30
  • Price/Cash Flow 53.73
  • Price/Book 6.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.84
  • Number of Estimates 1
  • High Estimate 0.84
  • Low Estimate 0.84
  • Prior Year 0.55
  • Growth Rate Est. (year over year) +52.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
197.60 +6.50%
on 10/15/18
278.62 -24.47%
on 10/01/18
-44.35 (-17.41%)
since 09/14/18
3-Month
197.60 +6.50%
on 10/15/18
278.62 -24.47%
on 10/01/18
-9.39 (-4.27%)
since 07/16/18
52-Week
126.50 +66.35%
on 12/01/17
278.62 -24.47%
on 10/01/18
+68.69 (+48.47%)
since 10/16/17

Most Recent Stories

More News
Ligand to Report Third Quarter 2018 Results on November 8th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2018 financial results on November 8, 2018. Ligand's CEO John Higgins, President and COO Matt...

LGND : 210.89 (+5.41%)
Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know

Ligand Pharmaceuticals (LGND) closed at $202.59 in the latest trading session, marking a -1.5% move from the prior day.

LGND : 210.89 (+5.41%)
Ligand Announces the Close of its Acquisition of Vernalis

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as a subsidiary of Ligand. Vernalis...

LGND : 210.89 (+5.41%)
VNLPF : 0.2190 (unch)
Watch for Ligand Pharm to Potentially Rebound After Falling 1.84% Yesterday

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $241.75 to a high of $251.50. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $243.98...

LGND : 210.89 (+5.41%)
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer

Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the launch of a Phase 2 trial...

LGND : 210.89 (+5.41%)
bluebird's MAA for LentiGlobin Gene Therapy Accepted by EMA

bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.

LGND : 210.89 (+5.41%)
CELG : 84.04 (+2.70%)
BLUE : 131.10 (+5.06%)
CLBS : 4.67 (+1.74%)
Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals

Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals

MCFT : 35.43 (+5.86%)
LGND : 210.89 (+5.41%)
NR : 10.00 (-0.10%)
WTW : 67.67 (+3.33%)
27.4% Return Seen to Date on SmarTrend Ligand Pharm Call (LGND)

SmarTrend identified an Uptrend for Ligand Pharm (NASDAQ:LGND) on June 21st, 2018 at $199.56. In approximately 4 months, Ligand Pharm has returned 27.41% as of today's recent price of $254.26.

LGND : 210.89 (+5.41%)
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK

Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.

LGND : 210.89 (+5.41%)
CLBS : 4.67 (+1.74%)
ALNY : 82.45 (+3.05%)
ATHX : 2.13 (+2.40%)
VistaGen Up on Fast Track Designation to Pain Candidate

VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.

LGND : 210.89 (+5.41%)
CLBS : 4.67 (+1.74%)
ALKS : 42.21 (+1.66%)
VTGN : 2.31 (+11.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 212.28
1st Resistance Point 206.17
Last Price 211.18
1st Support Level 195.78
2nd Support Level 191.50

See More

52-Week High 278.62
Fibonacci 61.8% 220.51
Last Price 211.18
Fibonacci 50% 202.56
Fibonacci 38.2% 184.61
52-Week Low 126.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar